Tools
Tools
Livermore, David M. 
ORCID: https://orcid.org/0000-0002-9856-3703, Mushtaq, Shazad, Vickers, Anna and Woodford, Neil
(2023)
Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
International Journal of Antimicrobial Agents, 61 (5).
ISSN 0924-8579
Preview |
PDF (Livermore_etal_2023_IJAA)
Available under License Creative Commons Attribution. Download (876kB) | Preview |
Abstract
Aztreonam/avibactam is being developed on the rationale that aztreonam evades metallo-β-lactamases (MBLs) whilst avibactam protects aztreonam against co-produced serine β-lactamases. This study measured the activity of aztreonam/avibactam against MBL-producing Enterobacterales referred to the UK Health Security Agency in 2015, 2017 and 2019. Minimum inhibitory concentrations (MICs) were determined by broth microdilution, and genome sequences were determined with Illumina technology. For Klebsiella and Enterobacter spp. with NDM, IMP or VIM enzymes, the MICs of aztreonam/avibactam were distributed unimodally, with >90% of isolates inhibited at 1+4 mg/L, and all inhibited at 8+4 mg/L. Over 85% of Escherichia coli with NDM carbapenemases were inhibited at 8+4 mg/L, but their MIC distribution was multi-modal with major peaks at 0.12 and 8 mg/L. Forty-eight of 50 NDM E. coli with high aztreonam/avibactam MICs (defined as ≥8 mg/L) had YRIK inserted after amino acid 333 of penicillin-binding protein (PBP)3, or had a YRIN insert plus an acquired AmpC β-lactamase, commonly CMY-42. Ten of 15 E. coli with moderately raised aztreonam/avibactam MICs (defined as 0.5–4 mg/L) had YRIN inserts without acquired AmpC. Twenty-two of 24 E. coli isolates with normal MICs (defined as 0.03–0.25 mg/L) lacked PBP3 inserts. YRIK inserts were associated with E. coli ST405, and YRIN inserts with ST167; however, many isolates with high or moderately raised MICs were clonally diverse. No substantive MIC distribution shifts occurred across the three survey years; ST405 isolates with YRIK comprised more high-MIC organisms in 2019 compared with earlier years, but the apparent increase lacked significance (P>0.05).
| Item Type: | Article |
|---|---|
| Additional Information: | Funding: This work was supported by Pfizer. |
| Uncontrolled Keywords: | avibactam,escherichia coli,metallo-β-lactamases,ndm carbapenemase,pbp inserts,penicillin-binding protein (pbp)3,microbiology (medical),infectious diseases,pharmacology (medical) ,/dk/atira/pure/subjectarea/asjc/2700/2726 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 03 Mar 2023 15:30 |
| Last Modified: | 11 Jan 2024 01:38 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/91357 |
| DOI: | 10.1016/j.ijantimicag.2023.106776 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |